Search Results: PARP inhibitor

• Health & Medicine

Experimental drug may work in many cancers

Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today.

6 October 2009

• Health & Medicine

Olaparib approved for 800 prostate and breast cancer patients in England

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

11 April 2023

• Health & Medicine

Women in science: Cancer research pioneers – part 1

As our 20th anniversary year draws to a close, we're celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more. As our 20th anniversary year draws to a close, we're celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more.

18 January 2023

• Science & Technology
• Health & Medicine

Our most important cancer research stories of 2022

This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months.  This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months. 

14 December 2022

• Health & Medicine

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

13 September 2022

• Health & Medicine

COVID-19 vaccine and cancer – latest updates

Recently, news of a COVID-19 vaccine has dominated headlines. We've summarised all the information that is out there, with rolling updates, in our new vaccine blog post. Recently, news of a COVID-19 vaccine has dominated headlines. We've summarised all the information that is out there, with rolling updates, in our new vaccine blog post.

18 July 2022

• For Researchers

The award-winning team transforming breast cancer treatment

We spoke to Professor Andrew Tutt about how you build a successful scientific team, the importance of translation and why you always need a touch of humbleness… We spoke to Professor Andrew Tutt about how you build a successful scientific team, the importance of translation and why you always need a touch of humbleness…

10 April 2022

• Science & Technology
• Health & Medicine

Diving into our role in 50 top cancer drugs

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today. To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today.

9 February 2022

• For Researchers

Reflections from our chief scientist: The rise of the whole organism

Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach. Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach.

4 February 2022

• Health & Medicine

120 years of discovery: 10 ways we’ve changed the story for people with cancer

From a legacy of life-saving medicines to developing new tools to detect cancer, our scientists have been at the forefront of cancer research for 120 years. From a legacy of life-saving medicines to developing new tools to detect cancer, our scientists have been at the forefront of cancer research for 120 years.

2 February 2022

• Science & Technology
• Health & Medicine

Prising open the trap: Getting to grips with targeted cancer drug resistance

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding. Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

10 January 2022